Why is C4 Therapeutics stock gaining today?
C4 Therapeutics shares rose 3.8% in morning trading after the company reported Q2 2026 results. Net loss per share was $0.18, better than the $0.21 consensus, but revenue was $6.64M versus $8.2M expected, citing research wind-downs under Merck and Merck KGaA collaborations. Management said cemsidomide Phase 2 MOMENTUM and Phase 1b combo studies remain on track for 2027 data.
How this was made
The 30-second read
Why it matters
EPS beat supported the stock, but revenue missed consensus and was partially affected by wind-down of certain research activities under Merck and Merck KGaA collaborations. Management reiterated that key cemsidomide trial readouts are still targeted for 2027.
Market read
A same-day earnings surprise plus reaffirmed clinical milestones explains the move, with revenue weakness tempering enthusiasm.
What to watch
Investors may discount the 2027 readout catalyst if trial execution risk rises, and the EPS beat may be influenced by non-recurring items not detailed in the article.
Background
The article frames today’s move as a reaction to C4 Therapeutics’ Q2 2026 financial results and accompanying Form 8-K, with investors also watching CPI.
Ticker impact
C4 Therapeutics shares rose 3.8% after Q2 2026 results beat EPS expectations, with management reaffirming cemsidomide Phase 2 MOMENTUM and Phase 1b combo timelines.
Near-term upside bias, but likely capped by the revenue shortfall and collaboration wind-down commentary.
The article cites a same-day EPS beat and management’s pipeline milestone reaffirmation as the primary catalyst, while explicitly noting revenue missed consensus and was impacted by Merck/Merck KGaA research wind-downs.
Market effects
Limited sympathy signal for targeted protein degradation peers, suggesting the catalyst is idiosyncratic rather than sector-wide.
No meaningful regional spillover indicated; major indices were mixed/flat.
No direct global macro or cross-border deal/regulatory impact described.
Counterpoint
The revenue miss and collaboration wind-down could outweigh the EPS beat if investors focus on top-line durability rather than milestone timing.
Key entities
- companyC4 Therapeutics
Clinical-stage biopharmaceutical company whose Q2 2026 results and pipeline milestone reaffirmation drove the stock’s morning gain.
- product_candidatecemsidomide
Lead program referenced with Phase 2 MOMENTUM and Phase 1b combination study timelines.
- collaborationMerck and Merck KGaA collaborations
Partnerships cited as contributing to a partial revenue impact via wind-down of certain research activities.
